Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX1 | P09601 | 2/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.64 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | QPCT | Q16769 | 1/20 | 0.61 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.61 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9996042 | 0.98 | HMOX1 (0.69) | HMOX1CYP19A1TBXAS1CYP1A2POLB | |
| SCHEMBL12045329 | 0.98 | HMOX1 (0.69) | HMOX1CYP19A1TBXAS1CYP1A2POLB | |
| Hydrochloric Acid SCHEMBL9996078 | 0.97 | HMOX1 (0.68) | HMOX1CYP19A1TBXAS1CYP1A2POLB | |
| SCHEMBL3160306 | 0.95 | CYP19A1 (0.71) | HMOX1CYP19A1TBXAS1CYP1A2POLB | |
| Hydrochloric Acid SCHEMBL411704 | 0.93 | CYP19A1 (0.69) | HMOX1CYP19A1TBXAS1CYP1A2POLB | |
| SCHEMBL12045347 | 0.91 | HMOX1 (0.84) | HMOX1CYP19A1TBXAS1 | |
| Hydrochloric Acid SCHEMBL9996059 | 0.89 | HMOX1 (0.81) | HMOX1CYP19A1TBXAS1 | |
| SCHEMBL230077 | 0.89 | CYP19A1 (0.63) | HMOX1CYP19A1TBXAS1CYP1A2POLB | |
| SCHEMBL227437 | 0.89 | CYP19A1 (0.63) | HMOX1CYP19A1TBXAS1CYP1A2POLB | |
| SCHEMBL19681102 | 0.88 | HMOX1 (0.65) | HMOX1CYP19A1TBXAS1QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-7148214-B1 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-12 | — | — | US | disclosed |
| US-7087595-B2 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-08 | — | — | US | disclosed |
| EP-1144411-B1 | ANTIHISTAMINIC SPIRO COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050026901-A1 | Antiallergens; vision disorders | JANSSENS FRANS EDUARD (BE) | 2005-02-03 | — | — | US | disclosed |
| EP-1144411-A1 | ANTIHISTAMINIC SPIRO COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000037470-A1 | ANTIHISTAMINIC SPIRO COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
| EP-0071060-B1 | 6-(4-(OMEGA-(1-IMIDAZOLYL)-ALKYL)-PHENYL)-3-OXO-2,3,4,5-TETRAHYDRO-PYRIDAZINES AND THEIR ACID-ADDITION SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM | A. Nattermann & Cie. GmbH (DE) | 1986-09-10 | — | — | EP | disclosed |
| US-4507298-A | 6-{4-(ω-(1-imidazolyl)-alkyl-phenyl}-3-oxo-2,3,4,5-tetrahydro-pyridazines and acid addition salts thereof, and a process for the treatment of inflammatory, atherosclerotic and thromboembolic illnesses in humans | A. NATTERMANN & CIE GMBH (DE) | 1985-03-26 | — | — | US | disclosed |
| EP-0071060-A2 | 6-(4-(Omega-(1-imidazolyl)-alkyl)-phenyl)-3-oxo-2,3,4,5-tetrahydro-pyridazines and their acid-addition salts, process for their preparation and pharmaceutical compounds containing them | A. Nattermann & Cie. GmbH (DE) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | HMOX1 2/4885CYP19A1 884/4885TBXAS1 469/4885 |
| US-20050026901-A1 | Antiallergens; vision disorders | UACA, LTB4R, HLA-B | HMOX1 714/4885CYP19A1 454/4885TBXAS1 1399/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | HMOX1 1/4885CYP19A1 641/4885TBXAS1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.